Human recombinant interferonalpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot study.
The oral use of human recombinant interferonalpha-2b at 1,000 IU/ml/day appeared to provide only a transient benefit as compared with placebo for management of idiopathic recurrent superficial pyoderma in dogs. Further investigation using a larger population of dogs is needed to determine whether interferon is effective for long-term treatment of this condition.